Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Repositioning Drugs for PD, 2011
    Droxidopa Treatment for Cognitive Impairment in Parkinson's Disease

    Objective/Rationale:
    Memory, concentration, and other cognitive operations are sometimes impaired in Parkinson's disease (PD), but available treatment options are very limited. This project will test...

  • Rapid Response Innovation Awards, 2011
    Pathogenic Significance of the Hyperpolarization-activated Current (Ih) in the Degeneration of Dopaminergic Neurons

    Objective/Rationale:
    The neurotoxin MPTP is believed to kill nigral dopaminergic neurons by inhibiting mitochondrial metabolism, thus producing Parkinson’s signs in pre-clinical models. Recent studies...

  • MJFF Research Grant, 2011
    GeneGo LRRK2 Pathway Map - Laura Brovold (GeneGo/Thomson Reuters)

    Objective/Rationale:
    Human diseases are inherently complex and involve a multitude of interconnected proteins, which function in groups defined as pathways and complexes. In order to understand...

  • Dyskinesia, 2011
    Role of Gad1 in l-DOPA-induced dyskinesias

    Objective/Rationale:
    Levodopa remains the most efficient agent used for the Symptoms & Side Effects treatment of Parkinson’s disease. Unfortunately, levodopa administration for several years also...

  • MJFF Research Grant, 2011
    Estimating Neuroprotective Effects of Nigral AAV-NRTN Using Selective Reaction Monitoring to Quantitatively Measure p-erk1/2 Signaling Strength in Nigral DA Neurons

    Objective/Rationale:
    Pre-clinical studies indicate that neurotrophic factor gene therapy has the potential to attenuate, delay and perhaps prevent the progressive loss of nigral DA neurons in aging...

  • Dyskinesia, 2011
    Development of a Treatment for Dyskinesia Targeting Opioid Receptors

    Objective/Rationale:
    Levodopa-induced dyskinesias (LID) affect the majority of patients with advanced Parkinson’s disease, compounding their disability. Therefore, drugs that prevent or limit LID are...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.